The FDA approved a label update for Bristol-Myers Squibb’s Opdivo (nivolumab) that recommends dosing the anti-PD-1 mAb every four weeks rather than every two weeks for most indications, giving it a possible advantage over competitors like Merck & Co.’s Keytruda (pembrolizumab) and Roche’s Tecentriq (atezolizumab).
To provide FirstWord readers with rapid feedback on how Opdivo’s more flexible dosing schedule may impact the competitive immuno-oncology (I/O) landscape, we are hosting an expert call with a key opinion leader (KOL) this week.
Key topics that will be discussed during the call include, among other things… how you decide between I/O options at the moment; how and when will that change with Opdivo’s new dosing schedule; are there certain tumour types of treatment settings where the new dosing schedule will be especially impactful; will the impact of a less frequent dosing schedule be felt more in a big academic center or out in the community; and what impact might a less frequent dosing regimen for Opdivo have on its development and/or use as part of I/O combinations?
Ask the expert!
Furthermore, we invite FirstWord Pharma readers to submit their own questions for consideration. Please click here to do so. We can't guarantee that all questions submitted will be asked due to time constraints, but we will do our utmost to cover the important issues relating to the highly competitive I/O arena.
We endeavour to provide feedback from KOLs as quickly as possible. Interview content will be published for FirstWord Pharma PLUS subscribers to read. To be notified when the interview content is available please click here.
As always, FirstWord would very much like to receive your feedback and suggestions.
To read more KOL Views articles, click here.